News
Biotech cools off in August as capital markets weaken September 01, 2010 | Press Release
Biotech gets hot in July August 02, 2010 | Press Release
Shawn Cross appointed CEO of Burrill Merchant Banking Group July 28, 2010 | Press Release
See all News
Biotech 2009-Life Sciences: Navigating the Sea Change (PDF)
Sea change: Noun: a striking change, as in appearance, often for the better
Biotech 2009-Life Sciences: Navigating the Sea Change is the 23rd edition of this yearly publication. It provides a compass to guide you through the current financial market turmoil. The 400-plus page book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond.
Biotech 2009-Life Sciences: Navigating the Sea Change is the 23rd edition of this yearly publication. It provides a compass to guide you through the current financial market turmoil. The 400-plus page book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond.
The biotech industry has had nearly 40 years of easy access to inexpensive capital. The capital markets have permanently restructured, making access to capital more difficult and expensive to access. The changes mean:
§ Buy-side interest and resources are reduced.
§ Venture capitalist and private investors no longer can rely on IPOs for exits.
§ Big Pharma is not as eager to make deals. As these companies see it, technology will be cheaper to buy if they wait.
§ Falling oil prices may slow the momentum for alternate fuels.
Click here to view the table of contents.
NOTE: This is a single user license. This product is not for copying, redistribution, or posting on a corporate server. For a multi-user license, please contact Peter Winter at pwinter@b-c.com or 415-591-5474.
Add to cart$395.00